iLSTA: A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma

LSTA1 is a dual αV integrin and neuropilin-1 targeting peptide. It has been shown to improve penetration of co-administered anticancer drugs by targeting the tumour vasculature via its affinity for αV integrin. Once bound, it is cleaved by proteases to a linear peptide which binds to a second receptor called neuropilin-1. Through this mechanism, LSTA1  activates an uptake pathway that allows anticancer drugs to penetrate solid tumours more effectively and selectively. Preclinical studies have demonstrated the safety and efficacy of LSTA1, in addition to the enhanced action of chemotherapy. Finally, LSTA1 increases the CD8+ to CD4+ T cell ratio, thus priming the tumour immune landscape. This study will assess the impact of adding a PDL-1 molecule to LSTA1 and standard chemotherapy as first-line treatment in locally advanced PDAC.

This study aims to determine the safety and efficacy of LSTA1 in combination with durvalumab, gemcitabine, and nab-paclitaxel in subjects with locally advanced pancreatic ductal adenocarcinomas.